ladostigil hemitartrate

DRUG2 trials

Sponsors

Avraham Pharmaceuticals Ltd

Conditions

Alzheimer's DiseaseCognitive ImpairmentDementiaMemory LossMild Cognitive Impairment

Phase 2

Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease

CompletedNCT01354691

Avraham Pharmaceuticals LtdAlzheimer's Disease, Cognitive Impairment, Dementia +1

Start: 2011-02-28End: 2013-03-31Updated: 2020-07-30

A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment

CompletedNCT01429623

Avraham Pharmaceuticals LtdDementia, Mild Cognitive Impairment

Start: 2012-02-29End: 2016-09-30Updated: 2017-06-15

Related Papers

Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial.

2019-09-0650 citations